Yang Y, Fu KZ, Pan G. Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis. World J Gastrointest Surg 2024; 16(1): 228-238 [PMID: 38328320 DOI: 10.4240/wjgs.v16.i1.228]
Corresponding Author of This Article
Gu Pan, BSc, Nurse, Department of Gastroenterology III, Heilongjiang Provincial Hospital, No. 405 Guogoli Street, Nangang District, Harbin 150036, Heilongjiang Province, China. pangu6196@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jan 27, 2024; 16(1): 228-238 Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.228
Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis
Yue Yang, Kan-Zuo Fu, Gu Pan
Yue Yang, Gu Pan, Department of Gastroenterology III, Heilongjiang Provincial Hospital, Harbin 150036, Heilongjiang Province, China
Kan-Zuo Fu, Department of Nursing, The Second Hospital of Harbin, Harbin 150056, Heilongjiang Province, China
Co-first authors: Yue Yang and Kan-Zuo Fu.
Author contributions: Yang Y and Fu KZ wrote the manuscript; Yang Y, Fu KZ, and Pan G collected and analyzed the data; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gu Pan, BSc, Nurse, Department of Gastroenterology III, Heilongjiang Provincial Hospital, No. 405 Guogoli Street, Nangang District, Harbin 150036, Heilongjiang Province, China. pangu6196@126.com
Received: November 14, 2023 Peer-review started: November 14, 2023 First decision: December 8, 2023 Revised: December 19, 2023 Accepted: December 29, 2023 Article in press: December 29, 2023 Published online: January 27, 2024
Abstract
BACKGROUND
Oncostatin M (OSM) is a pleiotropic cytokine which is implicated in the pathogenesis of inflammatory bowel disease (IBD).
AIM
To evaluate the prognostic role of OSM in IBD patients.
METHODS
Literature search was conducted in electronic databases (Google Scholar, Embase, PubMed, Science Direct, Springer, and Wiley). Studies were selected if they reported prognostic information about OSM in IBD patients. Outcome data were synthesized, and meta-analyses were performed to estimate standardized mean differences (SMDs) in OSM levels between treatment responders and non-responders and to seek overall correlations of OSM with other inflammatory biomarkers.
RESULTS
Sixteen studies (818 Crohn’s disease and 686 ulcerative colitis patients treated with anti-tumor necrosis factor-based therapies) were included. OSM levels were associated with IBD severity. A meta-analysis found significantly higher OSM levels in non-responders than in responders to therapy [SMD 0.80 (0.33, 1.27); P = 0.001], in non-remitters than in remitters [SMD 0.75 (95%CI: 0.35 to 1.16); P < 0.0001] and in patients with no mucosal healing than in those with mucosal healing [SMD 0.63 (0.30, 0.95); P < 0.0001]. Area under receiver operator curve values showed considerable variability between studies but in general higher OSM levels were associated with poor prognosis. OSM had significant correlations with Simple Endoscopic Score of Crohn’s disease [r = 0.47 (95%CI: 0.25 to 0.64); P < 0.0001], Mayo Endoscopic Score [r = 0.35 (95%CI: 0.28 to 0.41); P < 0.0001], fecal calprotectin [r = 0.19 (95%CI: 0.08 to 0.3); P = 0.001], C-reactive protein [r = 0.25 (95%CI: 0.11 to 0.39); P < 0.0001], and platelet count [r = 0.28 (95%CI: 0.17 to 0.39); P < 0.0001].
CONCLUSION
OSM is a potential candidate for determining the severity of disease and predicting the outcomes of anti-tumor necrosis factor-based therapies in IBD patients.
Core Tip: Higher Oncostatin M (OSM) expression/levels are found to be associated with worse disease outcomes which shows that OSM can be used as a s surrogate marker of poor prognosis in inflammatory bowel disease patients treated with anti-tumor necrosis factor based therapies. Thus, OSM appears to be an attractive biomarker for patient selection and clinical decision-making. However, owing to the presence of heterogeneity in included studies, this evidence should be refined in future studies.
